Andrew Pierce, senior executive at French biotech Owkin, on how artificial intelligence can make the drug development process more efficient.

Retro Biosciences will back clinical trials for three drugs—including a potential Alzheimer’s disease treatment set to begin ...

SELLAS Life Sciences CEO Angelos Stergiou and "Some Future Day" author Marc Beckman predict artificial intelligence will ...

Artificial Intelligence (AI) was a buzzword around Wall Street for most of 2024. AI has shown immense promise but comes with ...

The biotech scene can be seen as fairly risky for new investors who want to put money to work. After all, it’s really tough ...

The imaging artificial intelligence developer Quibim has raised $50 million in venture capital funding, to support its work ...

L'Oréal -backed biotech firm Debut has released an artificial intelligence (AI)-powered ingredient discovery platform aimed ...

Debut, the biotech beauty leader, announced today the launch of BeautyORB™, an AI-powered innovation engine that provides a ...

AI, biotech and affordable clean energy will be the focus of an EU drive to make the bloc globally competitive and ensure it ...

Despite continued underperformance in 2024, the biotech sector enters 2025 with a brighter outlook driven by groundbreaking ...

The Warren-headquartered clinical-stage specialty immunotherapy biotechnology company focuses on the development of T-cell ...

BRUSSELS: Artificial intelligence (AI), biotech and affordable clean energy will be the focus of a European Union (EU) drive ...